Syngen Biotech Co (ROCO:8279) Beneish M-Score: -2.34 (As of Jul. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:8279 Syngen Biotech Co Ltd ROCO:8279
89 GF Score
Price NT$88.50
GF Value NT$158.15
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Syngen Biotech Co Beneish M-Score?

Syngen Biotech Co ROCO:8279 +1.03% 89 Beneish M-Score is -2.34 as of Jul. 22, 2026. GuruFocus rates ROCO:8279 with a GF Score™ of 89/100 and a GF Value™ of NT$158.15 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 825 Biotechnology companies, Syngen Biotech Co ranks worse than 51.03% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.34 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Syngen Biotech Co's Beneish M-Score or its related term are showing as below:

ROCO:8279' s Beneish M-Score Range Over the Past 10 Years
Min: -2.85   Med: -2.33   Max: -0.77
Current: -2.34

During the past 13 years, the highest Beneish M-Score of Syngen Biotech Co was -0.77. The lowest was -2.85. And the median was -2.33.


Syngen Biotech Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Syngen Biotech Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syngen Biotech Co Beneish M-Score Chart

Syngen Biotech Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.77 -2.32 -2.85 -2.57 -2.34

Syngen Biotech Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.57 -2.66 -2.53 -2.56 -2.34

ROCO:8279 vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, Syngen Biotech Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syngen Biotech Co Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Syngen Biotech Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Syngen Biotech Co's Beneish M-Score falls into.


ROCO:8279
89GF Score
Syngen Biotech Co Ltd ROCO:8279
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Syngen Biotech Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Syngen Biotech Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0308+0.528 * 1.0615+0.404 * 1.0561+0.892 * 1.061+0.115 * 0.9262
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9017+4.679 * -0.015711-0.327 * 0.8037
=-2.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was NT$462 Mil.
Revenue was 479.78 + 563.218 + 607.576 + 485.91 = NT$2,136 Mil.
Gross Profit was 134.684 + 194.689 + 220.29 + 173.922 = NT$724 Mil.
Total Current Assets was NT$1,141 Mil.
Total Assets was NT$3,048 Mil.
Property, Plant and Equipment(Net PPE) was NT$1,493 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$121 Mil.
Selling, General, & Admin. Expense(SGA) was NT$339 Mil.
Total Current Liabilities was NT$520 Mil.
Long-Term Debt & Capital Lease Obligation was NT$151 Mil.
Net Income was 37.89 + 85.016 + 87.546 + 61.141 = NT$272 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = NT$0 Mil.
Cash Flow from Operations was 74.411 + 181.339 + 0.137 + 63.596 = NT$319 Mil.
Total Receivables was NT$423 Mil.
Revenue was 474.784 + 555.555 + 515.692 + 467.561 = NT$2,014 Mil.
Gross Profit was 170.955 + 205.18 + 182.858 + 164.943 = NT$724 Mil.
Total Current Assets was NT$1,155 Mil.
Total Assets was NT$3,085 Mil.
Property, Plant and Equipment(Net PPE) was NT$1,533 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$115 Mil.
Selling, General, & Admin. Expense(SGA) was NT$354 Mil.
Total Current Liabilities was NT$520 Mil.
Long-Term Debt & Capital Lease Obligation was NT$324 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(462.141 / 2136.484) / (422.557 / 2013.592)
=0.216309 / 0.209852
=1.0308

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(723.936 / 2013.592) / (723.585 / 2136.484)
=0.359525 / 0.33868
=1.0615

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1141.183 + 1493.084) / 3048.09) / (1 - (1155.043 + 1533.015) / 3084.594)
=0.135765 / 0.128554
=1.0561

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2136.484 / 2013.592
=1.061

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(114.685 / (114.685 + 1533.015)) / (121.328 / (121.328 + 1493.084))
=0.069603 / 0.075153
=0.9262

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(339.065 / 2136.484) / (354.38 / 2013.592)
=0.158702 / 0.175994
=0.9017

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((151 + 519.576) / 3048.09) / ((324.192 + 520.156) / 3084.594)
=0.219999 / 0.273731
=0.8037

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(271.593 - 0 - 319.483) / 3048.09
=-0.015711

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Syngen Biotech Co has a M-score of -2.34 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.34 mean?
Syngen Biotech Co (ROCO:8279) has a Beneish M-Score of -2.34 as of Jul. 22, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Syngen Biotech Co and its competitors. According to the industry distribution chart, Syngen Biotech Co ranks #421 out of 825 companies in the Biotechnology industry, placing it in the top 51%.
Is Syngen Biotech Co's Beneish M-Score too high?
Syngen Biotech Co's current Beneish M-Score is -2.34. Based on the distribution chart, Syngen Biotech Co ranks #421 out of 825 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Syngen Biotech Co has a GF Score™ of 89/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Syngen Biotech Co's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Syngen Biotech Co ranks #421 out of 825 companies for Beneish M-Score. This places Syngen Biotech Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Syngen Biotech Co and its competitors. Syngen Biotech Co's current Beneish M-Score is -2.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syngen Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Syngen Biotech Co (ROCO:8279) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$158.15, compared to a current price of NT$88.50 — trading 44% below its estimated fair value. The current Beneish M-Score is -2.34. Syngen Biotech Co's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Syngen Biotech Co (ROCO:8279), the current Beneish M-Score is -2.34 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Syngen Biotech Co (ROCO:8279) Overvalued in 2026?

Based on GuruFocus' analysis, Syngen Biotech Co stock appears to be undervalued. The current stock price of NT$88.50 is trading 44% below its estimated GF Value™ of NT$158.15. GuruFocus considers Syngen Biotech Co to be Significantly Undervalued.

Key valuation signals for ROCO:8279:

  • Beneish M-Score: -2.34
  • GF Value™: NT$158.15 vs. price of NT$88.50 (44% below fair value)
  • GF Score™: 89/100 with 2 warning signs

No single metric tells the full story. See the ROCO:8279 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Syngen Biotech Co Business Description

Address Building A, NO.154, Kai-Yuan Road, Xinying District, Tainan, TWN, 73055
Syngen Biotech Co Ltd is a biotechnology company. It is engaged in the manufacturing, sales, and trading of microbial pharmaceutical raw materials. It also provides the design and development of health food and biochemical nutrition. The company's products include pharmaceutical ingredients, nutritional ingredients, biology fermentation products, biology agriculture and aquaculture products.
89GF Score

Get the complete analysis for ROCO:8279

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$88.50
Price
NT$158.15
GF Value